Alzheimer’s disease remains one of the most challenging neurodegenerative disorders worldwide. As global populations continue to age, the demand for disease-modifying therapies has grown dramatically. In recent years, Lecanemab injection has attracted significant attention as one of the first therapies designed to target the underlying pathology of Alzheimer’s disease rather than merely alleviating symptoms.

What Is Lecanemab?

Lecanemab is a humanized monoclonal antibody developed specifically for the treatment of early-stage Alzheimer’s disease. It selectively targets amyloid-beta protofibrils, which are believed to play a key role in the development and progression of the disease.

In Alzheimer’s disease, abnormal beta-amyloid proteins accumulate in the brain and form plaques. These plaques disrupt communication between neurons and eventually lead to cognitive decline.

Lecanemab works by binding to aggregated beta-amyloid proteins and helping the immune system clear them from the brain.This mechanism places Lecanemab within a new class of treatments known as anti-amyloid therapies, which aim to directly address the biological causes of Alzheimer’s disease.

Who Are the Target Patients?

Lecanemab has primarily been studied and used in patients with:

● Mild Cognitive Impairment (MCI) due to Alzheimer’s disease

● Early-stage Alzheimer’s disease

These patients typically show evidence of amyloid pathology in the brain, confirmed through imaging tests or cerebrospinal fluid biomarkers.

It is important to note that Lecanemab is not intended for patients with advanced Alzheimer’s disease, where widespread neuronal damage has already occurred.

Clinical Evidence and Effectiveness

Clinical trials have demonstrated that Lecanemab can slow cognitive and functional decline in patients with early Alzheimer’s disease.

In the large Phase III clinical study CLARITY‑AD, treatment with Lecanemab showed:

● Significant reduction of amyloid plaques in the brain

● Slower cognitive decline compared with placebo

● Improvements in certain daily functioning measures

Although Lecanemab is not considered a cure, these findings represent an important step forward in the development of disease-modifying therapies for Alzheimer’s disease.

Administration and Treatment Process

Lecanemab is administered through intravenous infusion, typically once every two weeks under medical supervision.

Because the therapy directly targets amyloid deposits in the brain, patients receiving treatment usually undergo careful monitoring, including:

● Routine brain imaging (MRI scans)

● Clinical monitoring for neurological symptoms

● Ongoing cognitive assessments

These monitoring procedures help ensure both the safety and effectiveness of the treatment.

Safety Considerations

Like other anti-amyloid antibodies, Lecanemab may be associated with a condition known as Amyloid‑related imaging abnormalities (ARIA).

ARIA may include:

● ARIA-E: Brain edema (swelling)

● ARIA-H: Small brain hemorrhages

Most cases observed in clinical trials were mild or asymptomatic, but MRI monitoring is recommended throughout treatment.

Other possible side effects include:

● Infusion-related reactions

● Headache

● Mild neurological symptoms

Why Lecanemab Matters

For decades,Alzheimer’s disease treatment focused mainly on symptom-management drugs, such as:

● Donepezil and other cholinesterase inhibitors

● Memantine

While these medications may improve symptoms, they do not alter the underlying disease progression.

Lecanemab represents a significant shift toward targeting the biological drivers of Alzheimer’s disease, particularly the accumulation of amyloid in the brain. Although long-term outcomes are still being studied, therapies like Lecanemab mark meaningful progress in efforts to slow disease progression worldwide.

Finally, I want to say

Lecanemab injection highlights the growing importance of precision biologic therapies in neurology. As scientific understanding of Alzheimer’s disease continues to evolve, targeted treatments may fundamentally reshape how this devastating condition is managed.

Although research is ongoing, therapies aimed at amyloid pathology have the potential to redefine future treatment strategies. Collaboration between healthcare providers and global pharmaceutical distributors such as Dengyue Pharmaceutical, which focuses on the international distribution of innovative and specialty medicines, plays a key role in ensuring that breakthrough therapies reach the patients who need them most.